What is Lantheus Holdings's oncology — revenue?

Lantheus Holdings (LNTH) reported oncology — revenue of $240.92M in Q1 2026.

What does oncology — revenue mean?

This metric represents the total net revenue generated from the sale of diagnostic and therapeutic products specifically within the oncology business segment. It reflects the commercial success of the company's portfolio designed to help healthcare providers identify, treat, and monitor cancer patients. By excluding assessed taxes, this figure provides a clear view of the underlying demand and market adoption of the company's oncology-focused medical solutions.

Lantheus Holdings LNTH Oncology — Revenue

Other product segments

PYLARIFY

$240.92M-6.5%

Cardiology

$84.63M—

Definity

$84.63M+6.8%

Neuraceq

$35.44M—

Neurology

$35.44M—

Strategic Partnerships And Other

$16.34M+52.1%

Licenseand Royalty Revenues

$7.48M+28.0%

SPECT Business

$0—

Similar metrics at other companies

JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax

$333.4M+45.3%

LLYOncology — Revenue

$2.27B+16.4%

GHOncology — Total Revenue

$204.95M+36.1%

NTRAOncology — Revenue recognized

$100K0.0%

MEDPOncology — Total Revenue

$237.56M+60.5%

GILDTotal Oncology — Total revenues

$810M+7.0%

Other financials

Income statement

See full

Revenue$377.3M+1.2%

Gross profit$230.9M-2.9%

Operating income$81.3M-20.3%

Net income$118.4M+62.3%

EPS (diluted)$1.80+76.5%

Balance sheet

See full

Cash & equivalents$500.3M-46.8%

Total debt$627.9M+1.8%

Total equity$1.2B+4.1%

Total assets$2.3B+14.2%

Cash flow

See full

Operating cash flow$125.1M+16.3%

CapEx$3.2M-63.0%

Free cash flow$121.9M+23.3%

Valuation

See full

Market cap$6.76B-26.3%

Enterprise value$6.89B-20.5%

P/E24.2×-10.2×

P/S4.4×-1.6×

Profitability

See full

Gross margin60.5%-3.6pp

Operating margin18.8%-10.7pp

Net margin18%+0.7pp

FCF margin24.4%-6.4pp

Returns & leverage

See full

Return on equity23.5%-1.7pp

Debt / equity0.5×0.0×

Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's oncology — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lantheus Holdings's oncology — revenue?: Lantheus Holdings (LNTH) reported oncology — revenue of $240.92M in Q1 2026.
What does oncology — revenue mean?: This metric represents the total net revenue generated from the sale of diagnostic and therapeutic products specifically within the oncology business segment. It reflects the commercial success of the company's portfolio designed to help healthcare providers identify, treat, and monitor cancer patients. By excluding assessed taxes, this figure provides a clear view of the underlying demand and market adoption of the company's oncology-focused medical solutions.